Work Here?
About Celerion
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Lincoln, Nebraska
Founded
2010
Overview
Celerion specializes in early phase drug development as a clinical research organization (CRO). The company provides a range of services to pharmaceutical and biotechnology companies, including clinical trial design, feasibility studies, project management, clinical and medical monitoring, bioanalytical sciences, and regulatory affairs. Celerion utilizes advanced bioanalytical techniques, particularly High Resolution Mass Spectrometry (HR MS), for metabolite profiling and identification, which distinguishes it from other CROs. The goal of Celerion is to assist clients in making informed early drug development decisions and to expedite the process of bringing new treatments to market, ultimately benefiting patients globally.
Simplify's Take
What believers are saying
- Growing demand for early-phase trials due to personalized medicine boosts Celerion's market.
- Advancements in bioanalytical technologies align with Celerion's expertise, enhancing service precision.
- Expansion in cell and gene therapy markets increases demand for Celerion's specialized services.
What critics are saying
- Emerging CROs in Asia offer cost-effective solutions, threatening Celerion's market share.
- AI advancements in drug discovery may reduce demand for traditional CRO services.
- Pharmaceutical industry consolidation could lead to fewer clients and larger contracts.
What makes Celerion unique
- Celerion specializes in early-phase drug development with over 40 years of experience.
- The company excels in metabolite profiling using High Resolution Mass Spectrometry (HR MS).
- Celerion's global operations offer comprehensive services from trial design to regulatory affairs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 4%1 year growth
↑ 4%2 year growth
↑ 4%Celerion was recognized as a CRO Leader in the quality, capabilities and reliability categories across two groups of respondents (small pharma and combined big and small pharma).
LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a leading clinical research organization, specializing in early clinical research and bioanalytical services, today announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory. In her new role, Goodman will oversee the strategic direction and operational performance of the Lincoln bioanalytical laboratory, leveraging her extensive experience in pharmaceutical research and development to drive innovation and design and execute customized bioanalysis for clients’ needs. She will be responsible for delivering on Celerion’s bioanalytical promise of industry-leading science, stringent compliance, and speed of delivery. With over 29 years of experience in the pharmaceutical industry, Goodman brings a wealth of knowledge in regulated GxP and discovery bioanalysis for both in-house and outsourced activities. Prior to joining Celerion, she held positions of increasing responsibility at AstraZeneca, MedImmune, and GlaxoSmithKline. Additionally, Goodman is a recognized thought leader, having recently served as a member of the Expert Working Group (EWG) for ICH M10 Bioanalytical Guidance Development and is active in numerous non-profit industry consortia such as EBF, AAPS, and DMDG
Celerion announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory.Post this
LINCOLN, Neb--(BUSINESS WIRE)--Celerion, a leading clinical research organization, proudly announces its recent achievement of obtaining the Clinical Laboratory Improvement Amendments (CLIA) certification for its state-of-the-art bioanalytical laboratory located in Lincoln, Nebraska. This significant milestone marks a pivotal step in Celerion’s commitment to advancing healthcare by integrating high-complexity testing and diagnostic services into its comprehensive suite of bioanalytical solutions. Celerion’s clinical laboratories, including their Lincoln site, have been CLIA-certified and CAP-accredited for over 25 years, which helped facilitate the CLIA certification of the laboratory. The CLIA certification is a testament to Celerion’s adherence to the highest standards of laboratory quality and competence. It enables Celerion to conduct non-waived testing on human specimens, a critical component in the health assessment, diagnosis, prevention, and treatment of diseases. This certification is particularly crucial as it allows Celerion to perform these vital tests prior to the full accreditation inspection by a CMS-approved agency, ensuring continuous advancement in patient care and clinical research
A sensitive and reliable method is needed in several different matrices, usually including blood, plasma, faeces, semen, urine and saliva. .
Celerion is Hiring for 30 Jobs on Simplify!
Find jobs on Simplify and start your career today
About Celerion
Industries
Biotechnology
Healthcare
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Lincoln, Nebraska
Founded
2010
Celerion is Hiring for 30 Jobs on Simplify!
Find jobs on Simplify and start your career today